- Adults (18-64 years)
- General population
- Hospital
- Intensive care unit
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Acute COVID-19
- Influenza
- Avian Influenza
- Pharmacological intervention
- Immunomodulator
- Baricitinib
- Statins
- Simvastatin
Central Data Repository
Explore the Central Data Repository: Use the filters and keyword search box on the left to find relevant studies. As you refine your search, the map and study list will automatically update to reflect your selections. Selecting a study from the list will provide detailed information about the specific study in question. A full legend can be found here
{content}
Study list
- General population
- Infants (<1 year)
- Children (1-11 years)
- Primary care
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- Elderly (≥65 years)
- Pregnant women
- Hospital
- Outpatient clinic
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Monoclonal antibodies
- Vaccination
- Nirsevimab
- Abrysvo
- Adults (18-64 years)
- Elderly (≥65 years)
- People at high risk of STIs
- Men who have sex with men
- PrEP users
- Outpatient clinic
- Monkeypox virus
- Mpox
- Sexually transmitted infection
- Serum
- Pharmacological intervention
- Vaccination
- MVA-BN
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Non-hospital health centre
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Metapneumovirus
- Parainfluenza Virus
- Rhinovirus
- Respiratory syncytial virus infection
- Influenza
- COVID-19
- Adenovirus infection
- Metapneumovirus infection
- Parainfluenza virus infection
- Rhinovirus infection
- Adults (18-64 years)
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Immunomodulator
- Colchicine
- Metformin
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Plitidepsin
- Antineoplastic agent
- Adults (18-64 years)
- General population
- Hospital
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Acute COVID-19
- Influenza
- Avian Influenza
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults (18-64 years)
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Blood sample
- Adults (18-64 years)
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Hospital
- Neisseria gonorrhoeae
- Sexually transmitted infection
- Adults (18-64 years)
- Elderly (≥65 years)
- Travelers
- Hospital
- Emergency department
- Arbovirus
- Chikungunya virus
- Vector-borne
- Dengue virus
- Zika virus
- Arboviral disease
- Vector-borne disease
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Neuromodulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Oxygen therapy
- Adults (18-64 years)
- Elderly (≥65 years)
- Fragile population
- Immunocompromised host
- Hospital
- Respiratory syncytial virus
- Respiratory syncytial virus infection
- Pharmacological intervention
- Vaccination
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Monkeypox virus
- Mpox
- Pharmacological intervention
- Antivirals
- Tecovirimat
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Cardiac coherence
- Adults (18-64 years)
- General population
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Neurostimulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Adolescents (12-17 years)
- Children (1-11 years)
- Outpatient clinic
- Arbovirus
- Dengue virus
- Vector-borne disease
- Arboviral disease
- Vector-borne disease
- Blood sample
- Pharmacological intervention
- Vaccination
- Qdenga
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Vimida
- Adults (18-64 years)
- Community
- Primary care
- SARS-CoV-2
- Influenza virus
- Influenza A(H5N1) virus
- Acute COVID-19
- Influenza
- Avian Influenza
- Pharmacological intervention
- Nitric Oxide Nasal Spray
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post-COVID-19
- Non pharmacological intervention
- Rehabilitation
- Stimulation
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Hospital
- Intensive care unit
- SARS-CoV-2
- Post-COVID-19
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Post-COVID-19